Document is current

Article History

Received: 23 October 2024

Accepted: 30 September 2025

First Online: 6 November 2025

Declarations

:

: A.O.E. is a consultant to Beckley Psytech Ltd. F.D. is a medical advisor to Beckley Psytech Ltd. M.S. is currently an employee of Beckley Psytech Ltd but was employed by King’s College London (until July 2022) and is currently completing a PhD with King’s College London. R.M. is a consultant to Beckley Psytech Ltd.

: Written informed consent was obtained from each participant before any trial-related procedures were performed. The dosing experience interview part of the BPL-003–103 study was optional. Subjects may decide not to do the interview without it affecting their participation in the rest of the main study. The information sheet and consent form for the main study contained an optional consent for the qualitative interview study part. If individuals declined to participate, or withdrew their participation, this decision was respected, and subjects are not required to give a reason for declining or withdrawing their participation. This was made clear to patients on the information sheet and by researchers during the consent process.

: This trial was conducted in accordance with International Council for Harmonisation Good Clinical Practice guidelines and ethical principles that have their origin in the Declaration of Helsinki. Protocols were approved by the Medicines and Healthcare Products Regulatory Agency and an independent recognised research ethics committee before eligibility screening. Audio recordings and demographic information of participants were stored on separate secure servers.